Department of Defense Grant: Investigator-Initiated Translational Research for Lung Cancer

This mechanism is intended to fund a broad range of translational studies, including, but not limited to, the following:

• Studies advancing /translating in vitro and/or animal studies to applications with human samples/cohorts.

• Late-stage preclinical work leading to/preparing for a clinical trial, e.g., Investigational New Drug (IND) application submission.

• Correlative studies that are associated with an ongoing or completed clinical trial and projects that develop endpoints for clinical trials.

Preliminary data to support the feasibility of the research hypotheses and research approaches are required; however, these data do not necessarily need to be derived from studies of lung cancer.

The anticipated direct costs budgeted for the entire period of performance for an FY17 LCRP Investigator-Initiated Translational Research Award will not exceed $400,000. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.

Military Relevance: The LCRP seeks to support research that is relevant to the healthcare needs of military Service members, Veterans, and their families. Military relevance will be considered in determining relevance to the mission of the DHP and FY17 LCRP during programmatic review. Investigators are strongly encouraged to consider the following characteristics as examples of how a project may demonstrate military relevance:

• Use of military or Veteran populations, biospecimens, data/databases, or programs in the proposed research.

• Collaboration with Department of Defense (DoD) or Department of Veterans Affairs (VA) investigators.

• Involvement of military consultants (Army, Air Force) or specialty leaders (Navy, Marine Corps) to the Surgeons General in a relevant specialty area.

• Description of how the knowledge, information, products, or technologies gained from the proposed research could be implemented in a dual-use capacity to address a military need that also benefits the civilian population.

• Explanation of how the project addresses an aspect of lung cancer that has direct relevance to military Service members, Veterans, or other military health system beneficiaries, including environmental exposures other than tobacco.

Use of Active Duty Military and VA Populations: If the proposed research plan involves access to active duty military and/or VA patient populations or resources, the PI is responsible for establishing and demonstrating such access. If possible, access to target active duty military and/or VA patient populations/resources should be confirmed at the time of application submission by inclusion of a letter of support, signed by the lowest-ranking person with approval authority, for studies involving active duty military Service members, Veterans, military and/or VA-controlled study materials, and military and/or VA databases. If access cannot be confirmed at the time of application submission, the Government reserves the right to withhold or revoke funding until the applicant has demonstrated support for and access to the relevant population(s) and/or resources. Note that access to a Veteran population for clinical studies may only be obtained by either collaboration with a VA investigator where the VA investigator has a substantial role in the research or by advertising to the general public.